Iron Substitution With Ferric Carboxymaltose as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction

NCT05477498 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Principal Investigator left institution

Conditions

Heart Failure With Normal Ejection Fraction
Iron-deficiency

Interventions

DRUG: Ferric carboxymaltose
DRUG: Placebo

Sponsor

Cantonal Hosptal, Baselland

Collaborators

[object Object]